Chronic fatigue syndrome patients need an effective therapeutic, leading expert argues



science-daily-logoAmpligen, the first drug ever seeking approval to treat chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME), recently hit another roadblock with the U.S. Food and Drug Administration (FDA). In its long quest to treat 1 million Americans suffering from this debilitating illness, the FDA advisory panel did not recommend the drug to be sold on the market, largely because CFS/ME doesn’t have clear biomarkers such as blood tests to define patients who most likely to respond to the drug. A leading clinician argues that the real loser is not Ampligen, but CFS/ME patients whose daily suffering continues to be unabated.

To read the full article, click here.